Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board. Dr. Der, a preeminent researcher in the science of RAS pathway sig...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Truist has initiated Verastem (VSTM +22.3%) with a buy saying that the stock is "undervalued" given its two clinical cancer candidates, VS-6766 and defactinib. The firm has a $6 price target (~436% upside based on Tuesday's close). Analyst Srikripa Devarakonda noted the base case is supported...
Report Selection Phase (Part A) Results from RAMP 201 and RAMP 202 Evaluating VS-6766 Alone and in Combination with Defactinib in Low-Grade Serous Ovarian Cancer (LGSOC) and KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), Respectively Report Preliminary Data from Phase 1/2 Tri...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate virtually at the following upcoming investor conferences: H.C. Wainwright BIOCONNECT Virtual Conference...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Gainers Cumberland Pharmaceuticals (NASDAQ:CPIX) +111%. Adagene (NASDAQ:ADAG) +12%. PLAYSTUDIOS (NASDAQ:MYPS) +7%. Verastem (NASDAQ:VSTM) +6%. Chimerix (NASDAQ:CMRX) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -6%. NRX Pharmaceuticals (NA...
News, Short Squeeze, Breakout and More Instantly...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...